Trial Profile
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Apr 2024
Price :
$35
*
At a glance
- Drugs Ozanimod (Primary) ; Interferon beta-1a
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms SUNBEAM
- Sponsors Celgene Corporation; Celgene International SARL; Receptos
- 02 Mar 2024 Updated findings from the Phase 3 SUNBEAM and DAYBREAK Extension Trials presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2024
- 29 Feb 2024 According to a Bristol-Myers Squibb media release, long-term disability progression in ozanimod-treated participants with relapsing multiple sclerosis from the SUNBEAM, RADIANCE, and DAYBREAK trials will be presented at the 9th annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024 in West Palm Beach, Florida taking place February 29 to March 2.
- 13 Oct 2023 Results of ad hoc analysis from NCT02294058 and NCT02576717 assessing aintenance of Clinically Meaningful Change in Symbol Digit Modalities Test Associated With Long-term Ozanimod Use presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis